Squamous cell carcinoma - Carcinoma De Células Escamosas
☆ Nos resultados de Stiftung Warentest de Alemaña de 2022, a satisfacción dos consumidores con ModelDerm foi só lixeiramente inferior á das consultas de telemedicina pagas.
Squamous cell carcinoma well differentiated ― Obsérvase unha queratose actínica adxacente.
References
Squamous cell carcinoma (SCC) é o segundo cancro de pel máis común nos Estados Unidos, despois de basal cell carcinoma. Normalmente comeza a partir de lesións precancerosas chamadas actinic keratosis , e pode estenderse a outras partes do corpo. A principal causa é a exposición á radiación ultravioleta (UV) do sol, que se acumula co paso do tempo. O tratamento xeralmente implica a extirpación cirúrxica, especialmente para SCC na cabeza e no pescozo. A radioterapia é unha opción para os pacientes maiores ou aqueles que non poden operarse. A inmunosupresión aumenta o risco de SCC. Aínda que é raro, o SCC pode estenderse, especialmente en pacientes con sistemas inmunitarios debilitados. As revisións regulares e a protección solar son importantes para aqueles con SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) é o segundo cancro máis común nas persoas, e os seus números están a aumentar. Aínda que o CSCC adoita mostrar un comportamento clínico benigno, pode estenderse tanto localmente como a outras partes do corpo. Os científicos identificaron vías específicas implicadas no desenvolvemento de CSCC, que conducen a novos tratamentos. O alto número de mutacións e o aumento do risco en pacientes inmunodeprimidos impulsaron o desenvolvemento da inmunoterapia. Esta revisión analiza as raíces xenéticas do CSCC e os últimos tratamentos dirixidos a moléculas específicas e ao sistema inmunitario.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnóstico e Tratamento
#Dermoscopy
#Skin biopsy